Recent advances in the molecular pathophysiology of rhabdomyosarcomas have highlighted genetic events that correlate with tumor behavior, chemoresistance, and thus outcome, including FGFR4 mutations and RAB3IP-HMGA2 fusion transcript expression. This evidence concerns the gene FGFR4 and neoplasm.